Antimicrobial Stewardship at Karuna Trust’s PHCs – Situational analysis of antibiotic usage and Medicines and Therapeutic Committees

Antimicrobial Stewardship at Karuna Trust’s PHCs – Situational analysis of antibiotic usage and Medicines and Therapeutic Committees

Antimicrobial Stewardship (AMS) is the new cluster at IPH that is being initiated by Sunitha. As part of this process, the first project is to incorporate AMS at 26 Karuna Trust Primary Health Centers (PHCs) in Karnataka by strengthening the Medicines and Therapeutics Committee (MTCs). An IEC application is being written up to seek ethical approval for the situational analysis phase of this project which aims to conduct a baseline study by documenting the current policies and practices that govern the pharmaceutical supply management of antibiotics at these 26 PHCs. Following the current prescribing indicators, including the prescribing pattern of antibiotics, the subsequent phase is designed to gather data on the Medicines and Therapeutics Indicators (MTI) for their PHC based contextual relevance before they could be incorporated as part of the Health Management Information System during the subsequent intervention phase of the project. This presentation is to seek feedback from peers at IPH so the IEC application is tweaked accordingly before submission on 15th Oct.

Speaker

Sunitha Srinivas

k

Affiliation

IPH Staff

Date

11-October-2018

Time

4:00 pm – 5.00 pm

Venue

Institute of Public Health, Bengaluru
#250, 2nd C Main, 2nd C Cross,
Girinagar Ist  Phase,
Bengaluru – 560085

The Blind Men and the Elephant: India’s Tuberculosis epidemic

The Blind Men and the Elephant: India’s Tuberculosis epidemic

The seminar will discuss my observations about India’s tuberculosis epidemic, seen through the perspective of my training in infectious diseases and microbiology. I have spent the last year working with the National Institute of Research in Tuberculosis on a research project that aimed at using protoemic methods to identify drug-resistance in TB. I spent a month in Mumbai, at the P.D. Hinduja hospital with Dr Camilla Rodrigues and Dr Zarir Udwadia, both world authorities on the microbiology and clinical management, respectively, of MDR-TB. Lastly, I visted hospitals and laboratories in rural India to try to understand their challenges with the diagnosis and management of TB.

Speaker

Husain Poonawala

k

Affiliation

IPH Adjunct Faculty

Date

22-August-2018

Time

4.00 pm – 5.00 pm

Venue

Institute of Public Health, Bengaluru
#250, 2nd C Main, 2nd C Cross,
Girinagar Ist  Phase,
Bengaluru – 560085

A Comparison of National Guidelines

A Comparison of National Guidelines

Visceral Leishmaniasis (VL) is an infectious disease predominantly transmitted by the sandfly. 90% of the cases of VL in the world occur in Brazil, Ethiopia, South Sudan, Sudan, India, Nepal, and Bangladesh. In 2005, the WHO South East Asia Region, responding to increasing incidences of VL in the Indian subcontinent, initiated a VL elimination program within India, Bangladesh, and Nepal. The aim was to reduce the incidence of VL to <1 case per 10,000 cases in districts/subdistricts within the three countries by 2015. Since then, the goalposts have shifted from 2015 to 2017 and, now, to 2020. Nepal and Bangladesh have traveled much further on the road to elimination than India has, Nepal having sustained the elimination target in the 12 once-endemic districts since 2012. In 2016, Bangladesh reached the elimination target in 99% of its endemic subdistricts (upazilas). Lagging closely behind, India has reached the elimination target in 85% of endemic subdistricts. The aim of this literature review predominantly on the national guidelines of VL elimination/control in the three countries as well as some research articles on the same is to compare the program in India with Bangladesh and Nepal, to identify similarities and differences between the programs, and to extrapolate data to see how India can learn from Bangladesh and Nepal to hasten its pace towards elimination of VL.

Speaker

Sayema

k

Affiliation

IPH Intern

Date

03-August-2018

Time

4.00 pm – 5.00 pm

Venue

Institute of Public Health, Bengaluru
#250, 2nd C Main, 2nd C Cross,
Girinagar Ist  Phase,
Bengaluru – 560085

Medicines for Visceral Leishmaniasis

Medicines for Visceral Leishmaniasis

WHO identified Visceral Leishmaniasis (VL) as a Category I disease (emerging and uncontrolled) and the support to the Elimination control programs in India, Nepal and Bangladesh were intensified in 2005. One of the key approaches that allows accelerated efforts towards the elimination process is by focusing on availability, affordability and accessibility of medicines used to treat VL. This presentation by Ms. Aishwarya Kulkarni, who has completed her BPharm, focuses on the evolution of the medicines for VL, their prices and some of the current issues in this regard.

Speaker

Aishwarya

k

Affiliation

IPH Intern

Date

26-July-2018

Time

3.00 pm – 4.00 pm

Venue

Institute of Public Health, Bengaluru
#250, 2nd C Main, 2nd C Cross,
Girinagar Ist  Phase,
Bengaluru – 560085